TNFRSF18 and neoplasm: Lastly, a GITR agonist antibody (DTA-1) has demonstrated its potential in enhancing CD8+ T cell response and reducing intra-tumoral Treg cell activities using transplantable tumor models including the B16 melanoma model (190, 192, 194).